Experts believe the biotech industry has opened up to some great opportunities for growth investors. Here are two examples.
Trading stocks online is a great way to be initiated into the world of stock trading. The major aim of stock trading is to be able to able to make profitable trades. Traders always search for stocks that have great growth potential. Growth leads to higher stock value. For online traders, the right stock trading software can give them a clear idea of the market and stock performance so they can have some idea as to whether the stocks they buy will end up becoming profitable.
For growth investors there are two great stocks out there in the biotech sector, according to experts:
Let’s analyze Omeros Corporation ($OMER). The company’s Omidria pupil-dilating solution is selling well, with sales jumping a whopping 212% higher than the levels in 2015. And more growth is expected. The solution helps in lens replacement and cataract removal surgeries. These procedures are performed frequently globally, and in the US alone they are performed around 4 million times annually. Omeros earned $41.4 million in product sales in 2016. Omidria is priced at around $465 per vial.
Ionis Pharmaceuticals ($IONS) is a stock that may not yet be enjoying recurring profitability. But it has significant potential, which is why it must be looked at by growth seeking investors. What gives Ionis the edge is its antisense drug development platform that enables it to predict the performance of its newly developed drugs in the treatment of specific ailments. This helps it to release five new drugs for clinical testing each year. This indicates that it can release drugs into the market at a faster rate.
Currently, Ionis has 24 drugs in the clinical study stage. Many of these drugs are developed with its licensing partners. The company’s research is fueled by its milestone payment revenue which it manages to accrue almost regularly thanks to its ability to partner up.
The Spinraza drug, for which Ionis partnered with Biogen, has the potential to be the first major profit-generating drug for the company. The spinal muscular atrophy drug costs as high as $750,000 in year one and $375,000 in subsequent years.